以上内容来自Benzinga Earnings专栏,原文如下:
Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.03 per share which met the analyst consensus estimate. This is a 25 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $210.60 million which missed the analyst consensus estimate of $211.62 million by 0.48 percent. This is a 7.12 percent increase over sales of $196.60 million the same period last year.